Mark E. Hatley

2.0k total citations
18 papers, 635 citations indexed

About

Mark E. Hatley is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Mark E. Hatley has authored 18 papers receiving a total of 635 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 12 papers in Pulmonary and Respiratory Medicine and 6 papers in Cancer Research. Recurrent topics in Mark E. Hatley's work include Sarcoma Diagnosis and Treatment (11 papers), Cancer-related molecular mechanisms research (4 papers) and Tumors and Oncological Cases (3 papers). Mark E. Hatley is often cited by papers focused on Sarcoma Diagnosis and Treatment (11 papers), Cancer-related molecular mechanisms research (4 papers) and Tumors and Oncological Cases (3 papers). Mark E. Hatley collaborates with scholars based in United States and New Zealand. Mark E. Hatley's co-authors include Rene L. Galindo, Matthew R. Garcia, David Finkelstein, Alfred G. Gilman, Rama Ranganathan, Steve W. Lockless, Scott K. Gibson, Jason A. Hanna, Catherine J. Drummond and Jerold E. Rehg and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Nature Communications.

In The Last Decade

Mark E. Hatley

18 papers receiving 632 citations

Peers

Countries citing papers authored by Mark E. Hatley

Since Specialization

Citations

This map shows the geographic impact of Mark E. Hatley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark E. Hatley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark E. Hatley more than expected).

Fields of papers citing papers by Mark E. Hatley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark E. Hatley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark E. Hatley. The network helps show where Mark E. Hatley may publish in the future.

Co-authorship network of co-authors of Mark E. Hatley

This figure shows the co-authorship network connecting the top 25 collaborators of Mark E. Hatley. A scholar is included among the top collaborators of Mark E. Hatley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark E. Hatley. Mark E. Hatley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	Developmental Heterogeneity of Rhabdomyosarcoma 2024 ·Cold Spring Harbor Perspectives in Medicine ·(unknown), Mark E. Hatley	2
2	Genetic context of oncogenic drivers dictates vascular sarcoma development in aP2‐Cre mice 2022 ·The Journal of Pathology ·Jason A. Hanna, Casey G. Langdon, Matthew R. Garcia, (unknown), Nadia A. Lanman, David Finkelstein, Jerold E. Rehg, Mark E. Hatley	6
3	Synthetic essentiality between PTEN and core dependency factor PAX7 dictates rhabdomyosarcoma identity 2021 ·Nature Communications ·Casey G. Langdon, (unknown), Matthew R. Garcia, Myron K. Evans, (unknown), (unknown), Jason A. Hanna, Catherine J. Drummond, (unknown), Patrick J. Leavey, David Finkelstein, Hongjian Jin, Patrick Schreiner, Jerold E. Rehg, Mark E. Hatley	14
4	The perfect PTEN – transcriptional regulation by PTEN dictates sarcoma identity 2021 ·Molecular & Cellular Oncology ·Casey G. Langdon, Mark E. Hatley	1
5	Pitfalls in the diagnosis of yolk sac tumor: Lessons from a clinical trial 2021 ·Pediatric Blood & Cancer ·(unknown), Alison Patterson, (unknown), Kenneth Chen, Jeffrey Gagan, Mark E. Hatley, A. Lindsay Frazier, James F. Amatruda, Theodore W. Laetsch, Dinesh Rakheja	1
6	PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma 2018 ·Oncogene ·Jason A. Hanna, Matthew R. Garcia, (unknown), Patrick J. Leavey, (unknown), (unknown), (unknown), (unknown), Yong‐Dong Wang, David Finkelstein, Mark E. Hatley	37
7	Hedgehog Pathway Drives Fusion-Negative Rhabdomyosarcoma Initiated From Non-myogenic Endothelial Progenitors 2018 ·Cancer Cell ·Catherine J. Drummond, Jason A. Hanna, Matthew R. Garcia, Daniel Devine, (unknown), David Finkelstein, Jerold E. Rehg, Mark E. Hatley	59
8	A Case of mistaken identity: Rhabdomyosarcoma development from endothelial progenitor cells 2018 ·Molecular & Cellular Oncology ·Catherine J. Drummond, Mark E. Hatley	7
9	Biallelic Dicer1 Loss Mediated by aP2-Cre Drives Angiosarcoma 2017 ·Cancer Research ·Jason A. Hanna, Catherine J. Drummond, Matthew R. Garcia, (unknown), David Finkelstein, Jerold E. Rehg, Mark E. Hatley	14
10	PAX7 is a required target for microRNA-206-induced differentiation of fusion-negative rhabdomyosarcoma 2016 ·Cell Death and Disease ·Jason A. Hanna, Matthew R. Garcia, (unknown), David Finkelstein, Kiran Kodali, Vishwajeeth Pagala, Xiaohua Wang, Junmin Peng, Mark E. Hatley	31
11	Probing for a deeper understanding of rhabdomyosarcoma: insights from complementary model systems 2015 ·Nature reviews. Cancer ·(unknown), Mark E. Hatley, Rene L. Galindo	88
12	MicroRNA-21 Aggravates Cyst Growth in a Model of Polycystic Kidney Disease 2015 ·Journal of the American Society of Nephrology ·Ronak Lakhia, Sachin Hajarnis, Darren R. Williams, Karam Aboudehen, Matanel Yheskel, Chao Xing, Mark E. Hatley, Vicente E. Torres, Darren P. Wallace, Vishal Patel	63
13	Endothelial Apoptosis in Pulmonary Hypertension Is Controlled by a microRNA/Programmed Cell Death 4/Caspase-3 Axis 2014 ·Hypertension ·Kevin P. White, Yvonne Dempsie, Paola Caruso, Emma Wallace, Robert A. McDonald, Hannah Stevens, Mark E. Hatley, Eva van Rooij, Nicholas W. Morrell, Margaret R. MacLean, Andrew H. Baker	78
14	A Mouse Model of Rhabdomyosarcoma Originating from the Adipocyte Lineage 2012 ·Cancer Cell ·Mark E. Hatley, Wei Tang, Matthew R. Garcia, David Finkelstein, Douglas P. Millay, Ning Liu, Jonathan M. Graff, Rene L. Galindo, Eric N. Olson	94
15	Allosteric determinants in guanine nucleotide-binding proteins 2003 ·Proceedings of the National Academy of Sciences ·Mark E. Hatley, Steve W. Lockless, Scott K. Gibson, Alfred G. Gilman, Rama Ranganathan	111
16	Expression, Purification, and Assay of Cytosolic (Catalytic) Domains of Membrane-Bound Mammalian Adenylyl Cyclases 2002 ·Methods in enzymology on CD-ROM/Methods in enzymology ·Mark E. Hatley, Alfred G. Gilman, Roger K. Sunahara	4
17	Isolation and Characterization of Constitutively Active Mutants of Mammalian Adenylyl Cyclase 2000 ·Journal of Biological Chemistry ·Mark E. Hatley, Benjamin K. Benton, Jun Xu, John P. Manfredi, Alfred G. Gilman, Roger K. Sunahara	15
18	Gas-phase methylation of the 2-hydroxypyridine/2-pyridone system by the dimethylchlorinium ion 1995 ·European Journal of Mass Spectrometry ·Richard A. J. O’Hair, Michael A. Freitas, Joseph A. R. Schmidt, Mark E. Hatley, Todd Williams	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact